NewAmsterdam Pharma Company has added more evidence that its CETP inhibitor obicetrapib is effective at lowering low-density lipoprotein cholesterol (LDL-C) in patients at risk of cardiovascular disease for whom existing therapies are insufficiently effective or tolerated. The results of the Phase III TANDEM trial combining the drug with ezetimibe generated optimism among analysts about the drug’s approvability and blockbuster sales potential.
NewAmsterdam’s Obicetrapib Boosts Approval Potential With Positive Combo Data
The company announced results of the TANDEM study combining the CETP inhibitor with ezetimibe, following successful monotherapy trial data announced in July
